SWTX Stock Overview
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
SpringWorks Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.21 |
| 52 Week High | US$62.00 |
| 52 Week Low | US$28.21 |
| Beta | 0.79 |
| 1 Month Change | -0.67% |
| 3 Month Change | 23.23% |
| 1 Year Change | 2.44% |
| 3 Year Change | 17.58% |
| 5 Year Change | 44.68% |
| Change since IPO | 104.20% |
Recent News & Updates
SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO
Apr 29SpringWorks Therapeutics, Inc.'s (NASDAQ:SWTX) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 12
Recent updates
SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO
Apr 29SpringWorks Therapeutics, Inc.'s (NASDAQ:SWTX) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 12SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz
Mar 11SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
Jan 13SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
Dec 31Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Dec 15Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results
Nov 15SpringWorks Therapeutics Merits A Speculative Buy
Nov 04SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
Aug 07Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
May 11We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09Shareholder Returns
| SWTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | -0.8% | 1.8% |
| 1Y | 2.4% | -6.6% | 9.5% |
Return vs Industry: SWTX exceeded the US Biotechs industry which returned -4.5% over the past year.
Return vs Market: SWTX underperformed the US Market which returned 9.6% over the past year.
Price Volatility
| SWTX volatility | |
|---|---|
| SWTX Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: SWTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SWTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 368 | Saqib Islam | www.springworkstx.com |
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial.
SpringWorks Therapeutics, Inc. Fundamentals Summary
| SWTX fundamental statistics | |
|---|---|
| Market cap | US$3.44b |
| Earnings (TTM) | -US$258.13m |
| Revenue (TTM) | US$191.59m |
17.9x
P/S Ratio-13.3x
P/E RatioIs SWTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SWTX income statement (TTM) | |
|---|---|
| Revenue | US$191.59m |
| Cost of Revenue | US$12.55m |
| Gross Profit | US$179.04m |
| Other Expenses | US$437.17m |
| Earnings | -US$258.13m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.47 |
| Gross Margin | 93.45% |
| Net Profit Margin | -134.73% |
| Debt/Equity Ratio | 0% |
How did SWTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 09:15 |
| End of Day Share Price | 2025/05/01 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SpringWorks Therapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Alec Stranahan | BofA Global Research |
| Cory Kasimov | Evercore ISI |